The Case for Early Treatment in Severe Aortic Stenosis (SAS) Patients: What the Latest Evidence Tells Us-Latest Evidence from the EARLY TAVR Trial: Treatment of Asymptomatic SAS Patients, Dr. Philippe Genereux,

Latest Evidence from the EARLY TAVR Trial: Treatment of Asymptomatic SAS Patients, Dr. Philippe Genereux,

Video Transcription

Video Summary

The presentation discusses the early TAVR (Transcatheter Aortic Valve Replacement) trial, focusing on asymptomatic severe aortic stenosis (AS) in patients aged 65 and above. This landmark trial demonstrated that early TAVR significantly reduced the primary endpoint—death, stroke, and unplanned cardiovascular hospitalization—with a 50% reduction in these outcomes and a notable improvement in quality of life and heart function compared to clinical surveillance. The trial also examined various sub-analyses, including the impact of age, cardiac biomarkers, and acute valve syndrome (AVS). The findings indicated consistent benefits across different age groups and suggested limited use of biomarkers in guiding TAVR timing. Additionally, a meta-analysis of related studies found that early intervention reduced heart failure hospitalization and stroke risk, supporting early TAVR for asymptomatic severe AS patients. Overall, prompt TAVR is recommended irrespective of age or biomarker levels to prevent severe complications associated with delayed intervention.

Keywords

TAVR trial

asymptomatic aortic stenosis

early intervention

quality of life

cardiac biomarkers